Daewoong Pharmaceutical announced on the 6th that it will commence full-scale development of an obesity treatment utilizing a microneedle patch loaded with GLP-1 (Glucagon-like peptide-1) analogues.
BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd.
Edwards Lifesciences announced it received CE Mark for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position.
Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003).
The Lubrizol Corporation announces the new EU food-grade approval for Carbopol® Polymers. The approval in the EU will enable nutraceutical manufacturers the ability to differentiate their portfolio and create unique new product claims.
Celltrion Group announced that the merger agreement between Celltrion, Inc. was approved at the extraordinary general meeting of shareholders (“EGM”) of the two companies held at Songdo Convensia and Sheraton Grand Incheon Hotel, respectively, on October 23, 2023.
Seegene's eco-friendly shipping box is composed of 12-paper layers, biodegradable films, recycled PET packaging, a vacuum insulation panel, dry ice, and ice packs. The materials are either 100% renewable or certified as "green" via organizations such as the Forest Stewardship Council (FSC) and the Ministry of Environment in Korea.
TriasMD, a musculoskeletal management company and parent of the DISC Surgery Centers, has announced its acquisition of Walnut Creek-based Pinnacle Surgery Center ("Pinnacle").
Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.